The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review)

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI

Xiao Y and Zhuang H: Effect of stereotactic radiotherapy on immune microenvironment of lung cancer. Front Immunol. 13:10258722022. View Article : Google Scholar : PubMed/NCBI

Billing DL and Rimner A: Results of radiation therapy as local ablative therapy for oligometastatic non-small cell lung cancer. Cancers (Basel). 13:57732021. View Article : Google Scholar : PubMed/NCBI

Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN and Hodge JW: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 170:6338–6347. 2003. View Article : Google Scholar : PubMed/NCBI

Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J and Hodge JW: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64:7985–7994. 2004. View Article : Google Scholar : PubMed/NCBI

Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG and Lord EM: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 174:7516–7523. 2005. View Article : Google Scholar : PubMed/NCBI

Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 203:1259–1271. 2006. View Article : Google Scholar : PubMed/NCBI

Schaue D, Ratikan JA, Iwamoto KS and McBride WH: Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 83:1306–1310. 2012. View Article : Google Scholar : PubMed/NCBI

Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, et al: Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 24:1845–1851. 2018. View Article : Google Scholar : PubMed/NCBI

Navarro-Martín A, Galiana IL, Berenguer Frances MA, Cacicedo J, Cañas Cortés R, Comas Anton S, Padrones Sánchez S, Bolívar Cuevas S, Parry R and Guedea Edo F: Preliminary study of the effect of stereotactic body radiotherapy (SBRT) on the immune system in lung cancer patients unfit for surgery: Immunophenotyping analysis. Int J Mol Sci. 19:39632018. View Article : Google Scholar : PubMed/NCBI

Zhou P, Chen D, Zhu B, Chen W, Xie Q, Wang Y, Tan Q, Yuan B, Zuo X, Huang C, et al: Stereotactic body radiotherapy is effective in modifying the tumor genome and tumor immune microenvironment in non-small cell lung cancer or lung metastatic carcinoma. Front Immunol. 11:5942122021. View Article : Google Scholar : PubMed/NCBI

Zhang T, Yu H, Ni C, Zhang T, Liu L, Lv Q, Zhang Z, Wang Z, Wu D, Wu P, et al: Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci Rep. 7:48662017. View Article : Google Scholar : PubMed/NCBI

Lockney NA, Zhang M, Morris CG, Nichols RC, Okunieff P, Swarts S, Zhang Z, Zhang B, Zhang A and Hoppe BS: Radiation-induced tumor immunity in patients with non-small cell lung cancer. Thorac Cancer. 10:1605–1611. 2019. View Article : Google Scholar : PubMed/NCBI

Lei QQ, Sui JD, Jin F, Luo HL, Shan JJ, Tang L, Wang Y and Wu YZ: Impact of high-dose rate radiotherapy on B and natural killer (NK) cell polarization in peripheral blood mononuclear cells (PBMCs) via inducing non-small cell lung cancer (NSCLC)-derived exosomes. Transl Cancer Res. 10:3538–3547. 2021. View Article : Google Scholar : PubMed/NCBI

Chen Y, Gao M, Huang Z, Yu J and Meng X: SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: A focus on the mechanisms, advances, and future challenges. J Hematol Oncol. 13:1052020. View Article : Google Scholar : PubMed/NCBI

Breen WG, Leventakos K, Dong H and Merrell KW: Radiation and immunotherapy: Emerging mechanisms of synergy. J Thorac Dis. 12:7011–7023. 2020. View Article : Google Scholar : PubMed/NCBI

Heinzerling JH, Mileham KF and Simone CB II: The utilization of immunotherapy with radiation therapy in lung cancer: A narrative review. Transl Cancer Res. 10:2596–2608. 2021. View Article : Google Scholar : PubMed/NCBI

He J and Hu Q: Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer. Front Immunol. 14:11265822023. View Article : Google Scholar : PubMed/NCBI

Luna J, Zafra J, Areses Manrique MC, Rodríguez A, Sotoca A, Fírvida JL, Chicas-Sett R, Mielgo X, Reyes JCT and Couñago F: New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer. World J Clin Oncol. 12:983–999. 2021. View Article : Google Scholar : PubMed/NCBI

Schlick B, Shields MD, Marin-Acevedo JA, Patel I and Pellini B: Immune checkpoint inhibitors and chemoradiation for limited-stage small cell lung cancer. Curr Treat Options Oncol. 23:1104–1120. 2022. View Article : Google Scholar : PubMed/NCBI

Azghadi S and Daly ME: Radiation and immunotherapy combinations in non-small cell lung cancer. Cancer Treat Res Commun. 26:1002982021. View Article : Google Scholar : PubMed/NCBI

Chicas-Sett R, Zafra-Martin J, Morales-Orue I, Castilla-Martinez J, Berenguer-Frances MA, Gonzalez-Rodriguez E, Rodriguez-Abreu D and Couñago F: Immunoradiotherapy as an effective therapeutic strategy in lung cancer: From palliative care to curative intent. Cancers (Basel). 12:21782020. View Article : Google Scholar : PubMed/NCBI

Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, et al: Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. Clin Cancer Res. 24:5368–5380. 2018. View Article : Google Scholar : PubMed/NCBI

Della Corte CM, Ciaramella V, Ramkumar K, Vicidomini G, Fiorelli A, Nardone V, Cappabianca S, Cozzolino I, Zito Marino F, Di Guida G, et al: Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. J Transl Med. 20:5412022. View Article : Google Scholar : PubMed/NCBI

Han MG, Wee CW, Kang MH, Kim MJ, Jeon SH and Kim IA: Combination of OX40 co-stimulation, radiotherapy, and PD-1 inhibition in a syngeneic murine triple-negative breast cancer model. Cancers (Basel). 14:26922022. View Article : Google Scholar : PubMed/NCBI

Pieper AA, Zangl LM, Speigelman DV, Feils AS, Hoefges A, Jagodinsky JC, Felder MA, Tsarovsky NW, Arthur IS, Brown RJ, et al: Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models. Front Immunol. 12:7638882021. View Article : Google Scholar : PubMed/NCBI

Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, et al: A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 51:2321–2329. 2015. View Article : Google Scholar : PubMed/NCBI

O'Brien MER, Anderson H, Kaukel E, O'Byrne K, Pawlicki M, Von Pawel J and Reck M; SR-ON-12 Study Group, : SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Ann Oncol. 15:906–914. 2004. View Article : Google Scholar : PubMed/NCBI

Zhou L, Wang XL, Deng QL, Du YQ and Zhao NQ: The efficacy and safety of immunotherapy in patients with advanced NSCLC: A systematic review and meta-analysis. Sci Rep. 6:320202016. View Article : Google Scholar : PubMed/NCBI

Xiong W, Zhao Y, Du H and Guo X: Current status of immune checkpoint inhibitor immunotherapy for lung cancer. Front Oncol. 11:7043362021. View Article : Google Scholar : PubMed/NCBI

Schild SE, Wang X, Bestvina CM, Williams T, Masters G, Singh AK, Stinchcombe TE, Salama JK, Wolf S, Zemla T, et al: Alliance A082002-a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. Clin Lung Cancer. 23:e317–e320. 2022. View Article : Google Scholar : PubMed/NCBI

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, et al: Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol. 15:59–68. 2014. View Article : Google Scholar : PubMed/NCBI

Kumar SS, Higgins KA and McGarry RC: Emerging therapies for stage III non-small cell lung cancer: stereotactic body radiation therapy and immunotherapy. Front Oncol. 7:1972017. View Article : Google Scholar : PubMed/NCBI

Modi C, Berim L, Isserow L, Malhotra J, Patel M, Langenfeld J, Aisner J, Almeldin D and Jabbour SK: Combining radiation therapy and immunotherapy for lung cancers: A narrative review. Shanghai Chest. 5:102021. View Article : Google Scholar : PubMed/NCBI

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P: Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18:895–903. 2017. View Article : Google Scholar : PubMed/NCBI

Thompson M and Rosenzweig KE: The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res. 8:48–57. 2019. View Article : Google Scholar : PubMed/NCBI

Murray L, Karakaya E, Hinsley S, Naisbitt M, Lilley J, Snee M, Clarke K, Musunuru HB, Ramasamy S, Turner R and Franks K: Lung stereotactic ablative radiotherapy (SABR): Dosimetric considerations for chest wall toxicity. Br J Radiol. 89:201506282016. View Article : Google Scholar : PubMed/NCBI

Welsh J, Thomas J, Shah D, Allen PK, Wei X, Mitchell K, Gao S, Balter P, Komaki R and Chang JY: Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 81:91–96. 2011. View Article : Google Scholar : PubMed/NCBI

Owen D and Sio TT: Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors. J Thorac Dis. 12:7024–7031. 2020. View Article : Google Scholar : PubMed/NCBI

Schneider BJ, Daly ME, Kennedy EB, Antonoff MB, Broderick S, Feldman J, Jolly S, Meyers B, Rocco G, Rusthoven C, et al: Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American society of clinical oncology endorsement of the American society for radiation oncology evidence-based guideline. J Clin Oncol. 36:710–719. 2018. View Article : Google Scholar : PubMed/NCBI

Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, et al: Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 35:709–717. 2017. View Article : Google Scholar : PubMed/NCBI

Tian S, Switchenko JM, Buchwald ZS, Patel PR, Shelton JW, Kahn SE, Pillai RN, Steuer CE, Owonikoko TK, Behera M, et al: Lung stereotactic body radiation therapy and concurrent immunotherapy: A multicenter safety and toxicity analysis. Int J Radiat Oncol Biol Phys. 108:304–313. 2020. View Article : Google Scholar : PubMed/NCBI

Korpics MC, Katipally RR, Partouche J, Cutright D, Pointer KB, Bestvina CM, Luke JJ, Pitroda SP, Dignam JJ, Chmura SJ and Juloori A: Predictors of pneumonitis in combined thoracic stereotactic body radiation therapy and immunotherapy. Int J Radiat Oncol Biol Phys. 114:645–654. 2022. View Article : Google Scholar : PubMed/NCBI

Simone CB II, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, et al: Radiation therapy for small cell lung cancer: An ASTRO clinical practice guideline. Pract Radiat Oncol. 10:158–173. 2020. View Article : Google Scholar : PubMed/NCBI

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin. 67:93–99. 2017. View Article : Google Scholar : PubMed/NCBI

Stahel RA, Ginsberg R, Havemann K, Hirsch FR, Ihde DC, Jassem J, Karrer K, Maurer LH, Osterlind K and van Houtte P: Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer. 5:119–126. 1989. View Article : Google Scholar

Jones GS, Elimian K, Baldwin DR, Hubbard RB and McKeever TM: A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung Cancer. 141:44–55. 2020. View Article : Google Scholar : PubMed/NCBI

Verma V, Simone CB II, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM, Hallemeier CL, Jabbour SK, Matthiesen CL, et al: Multi-institutional experience of stereotactic ablative radiation therapy for stage I small cell lung cancer. Int J Radiat Oncol Biol Phys. 97:362–371. 2017. View Article : Google Scholar : PubMed/NCBI

Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, Zhang G, Wang S, Hossain MS, Nazha B, et al: Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: A randomized phase II study. J Immunother Cancer. 8:e0013022020. View Article : Google Scholar : PubMed/NCBI

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, et al: Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 36:1611–1618. 2018. View Article : Google Scholar : PubMed/NCBI

Theelen WSEM, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, et al: Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI

Chen D, Patel RR, Verma V, Ramapriyan R, Barsoumian HB, Cortez MA and Welsh JW: Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiother Oncol. 150:114–120. 2020. View Article : Google Scholar : PubMed/NCBI

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015. View Article : Google Scholar : PubMed/NCBI

Huang YS, Li Z, Xiao ZF, Li D and Liu WY: Case report: Radiotherapy plus pneumococcal conjugate vaccine stimulates abscopal immune response in a patient with ALK+ NSCLC. Front Immunol. 13:9502522022. View Article : Google Scholar : PubMed/NCBI

de Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks J, Lin SY, et al: Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer. 10:e0043712022. View Article : Google Scholar

Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, et al: Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 7:382019. View Article : Google Scholar : PubMed/NCBI

Román-Jobacho A, Hernández-Miguel M, García-Anaya MJ, Gómez-Millán J, Medina-Carmona JA and Otero-Romero A: Oligometastatic non-small cell lung cancer: Current management. J Clin Transl Res. 7:311–319. 2021.PubMed/NCBI

Al-Shafa F, Arifin AJ, Rodrigues GB, Palma DA and Louie AV: A Review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: Where will the evidence lead? Front Oncol. 9:5432019. View Article : Google Scholar : PubMed/NCBI

Milano MT, Biswas T, Simone CB II and Lo SS: Oligometastases: History of a hypothesis. Ann Palliat Med. 10:5923–5930. 2021. View Article : Google Scholar : PubMed/NCBI

Bates JE and Milano MT: Prognostic significance of sites of extrathoracic metastasis in patients with non-small cell lung cancer. J Thorac Dis. 9:1903–1910. 2017. View Article : Google Scholar : PubMed/NCBI

Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RM, Troost EG, Hochstenbag MM, Smit EF and Dingemans AM: Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. Eur J Cancer. 51:2534–2544. 2015. View Article : Google Scholar : PubMed/NCBI

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, et al: Local consolidative therapy vs maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 37:1558–1565. 2019. View Article : Google Scholar : PubMed/NCBI

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, et al: Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial. JAMA Oncol. 4:e1735012018. View Article : Google Scholar : PubMed/NCBI

Brandão M, Durieux V and Berghmans T: Current and future research efforts in oligometastatic non-small cell lung cancer-a systematic review. Transl Lung Cancer Res. 10:3473–3485. 2021. View Article : Google Scholar : PubMed/NCBI

Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, et al: Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: A phase 2 trial. JAMA Oncol. 5:1283–1290. 2019. View Article : Google Scholar : PubMed/NCBI

Watanabe T, Firat E, Scholber J, Gaedicke S, Heinrich C, Luo R, Ehrat N, Multhoff G, Schmitt-Graeff A, Grosu AL, et al: Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature. Cancer Immunol Immunother. 69:1823–1832. 2020. View Article : Google Scholar : PubMed/NCBI

Griswold CR, Kerrigan K and Patel SB: Combination of local ablative therapy and continuation of immune checkpoint inhibitor (ICI) therapy provides durable treatment response past oligometastatic progression in NSCLC: A case report. Case Rep Oncol. 12:866–871. 2019. View Article : Google Scholar : PubMed/NCBI

Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, et al: Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): Primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23:781–792. 2022. View Article : Google Scholar : PubMed/NCBI

Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, et al: Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled open-label phase II trial. BMC Cancer. 20:5572020. View Article : Google Scholar : PubMed/NCBI

Van Limbergen EJ, Hoeben A, Lieverse RIY, Houben R, Overhof C, Postma A, Zindler J, Verhelst F, Dubois LJ, De Ruysscher D, et al: Toxicity of L19-interleukin 2 combined with stereotactic body radiation therapy: A phase 1 study. Int J Radiat Oncol Biol Phys. 109:1421–1430. 2021. View Article : Google Scholar : PubMed/NCBI

Liu Y, Jiang S, Lin Y, Yu H, Yu L and Zhang X: Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis. Front Oncol. 12:10665572022. View Article : Google Scholar : PubMed/NCBI

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI

Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J and McGarry RC: Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: A prospective study. Int J Radiat Oncol Biol Phys. 85:1325–1331. 2013. View Article : Google Scholar : PubMed/NCBI

Wang Z, Qiang Y, Shen Q, Zhu XX and Song Y: Neoadjuvant programmed cell death protein 1 blockade combined with stereotactic body radiation therapy for stage III(N2) non-small cell lung cancer: A case series. Front Oncol. 12:7792512022. View Article : Google Scholar : PubMed/NCBI

Luna J, Sotoca A, Fernández P, Miralles C and Rodríguez A: Recent advances in early stage lung cancer. J Clin Transl Res. 7:163–174. 2021.PubMed/NCBI

Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, et al: Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial. Lancet Oncol. 20:494–503. 2019. View Article : Google Scholar : PubMed/NCBI

Daly ME, Redman M, Simone CB, Monjazeb AM, Bauman JR, Hesketh P, Feliciano J, Kashani R, Steuer C, Ganti AK, et al: SWOG/NRG S1914: A randomized phase III trial of induction/consolidation atezolizumab + SBRT vs SBRT alone in high risk, early-stage NSCLC (NCT#04214262). Int J Radiat Oncol Biol Phys. 114:e4142022. View Article : Google Scholar

Hallqvist A, Koyi H, de Petris L, Lindberg K, Farooqi S, Helland Å, Wikström A, Johansson M, Planck M, Lindberg L, et al: 63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID). J Thorac Oncol. 16 (Suppl):S729–S730. 2021. View Article : Google Scholar

Bezjak A, Paulus R, Gaspar LE, Timmerman RD, Straube WL, Ryan WF, Garces YI, Pu AT, Singh AK, Videtic GM, et al: Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. J Clin Oncol. 37:1316–1325. 2019. View Article : Google Scholar : PubMed/NCBI

Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, et al: 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 123:3031–3039. 2017. View Article : Google Scholar : PubMed/NCBI

Verma V and Simone CB II: Approaches to stereotactic body radiation therapy for large (≥5 centimeter) non-small cell lung cancer. Transl Lung Cancer Res. 8:70–77. 2019. View Article : Google Scholar : PubMed/NCBI

Ichinose Y, Yano T, Yokoyama H, Inoue T, Asoh H and Katsuda Y: The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer. A potential risk of limited resection. J Thorac Cardiovasc Surg. 108:684–686. 1994. View Article : Google Scholar : PubMed/NCBI

Strauss GM, Herndon JE II, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, et al: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol. 26:5043–5051. 2008. View Article : Google Scholar : PubMed/NCBI

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI

National Comprehensive Cancer Network, . Non-small cell lung cancer. (version 2.2024). 2024.

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI

Zhao L, Liu C, Xie G, Wu F and Hu C: Multiple primary lung cancers: A new challenge in the era of precision medicine. Cancer Manag Res. 12:10361–10374. 2020. View Article : Google Scholar : PubMed/NCBI

Boyle JM, Tandberg DJ, Chino JP, D'Amico TA, Ready NE and Kelsey CR: Smoking history predicts for increased risk of second primary lung cancer: A comprehensive analysis. Cancer. 121:598–604. 2015. View Article : Google Scholar : PubMed/NCBI

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, et al: Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74:5458–5468. 2014. View Article : Google Scholar : PubMed/NCBI

Woody S, Hegde A, Arastu H, Peach MS, Sharma N, Walker P and Ju AW: Survival is worse in patients completing immunotherapy prior to SBRT/SRS compared to those receiving it concurrently or after. Front Oncol. 12:7853502022. View Article : Google Scholar : PubMed/NCBI

Bestvina CM, Pointer KB, Karrison T, Al-Hallaq H, Hoffman PC, Jelinek MJ, Juloori A, Melotek JM, Murgu S, Partouche J, et al: A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J Thorac Oncol. 17:130–140. 2022. View Article : Google Scholar : PubMed/NCBI

Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, et al: Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: Outcomes, toxicities, and low-dose radiation-related abscopal responses. Cancer Immunol Res. 7:1903–1909. 2019. View Article : Google Scholar : PubMed/NCBI

Windisch P and Guckenberger M: Randomized phase II trial reporting overall survival advantage by adding local consolidative therapy to systemic therapy for oligometastatic non-small cell lung cancer: Another step forward on the long road of evidence-based medicine for oligometastatic disease. J Thorac Dis. 11 (Suppl 15):S1869–S1873. 2019. View Article : Google Scholar : PubMed/NCBI

Mitchell P, Thatcher N, Socinski MA, Wasilewska-Tesluk E, Horwood K, Szczesna A, Martín C, Ragulin Y, Zukin M, Helwig C, et al: Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 26:1134–1142. 2015. View Article : Google Scholar : PubMed/NCBI

Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, et al: P Phase II study of immunotherapy with tecemotide and bevacizumab after chemoradiation in patients with unresectable stage III non-squamous non-small-cell lung cancer (NS-NSCLC): A trial of the ECOG-ACRIN cancer research group (E6508). Clin Lung Cancer. 21:520–526. 2020. View Article : Google Scholar : PubMed/NCBI

Alite F, Shaikh PM and Mahadevan A: Influence of dexamethasone premedication on acute lung toxicity in lung SBRT. Front Oncol. 12:8375772022. View Article : Google Scholar : PubMed/NCBI

Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, et al: Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 36:2872–2878. 2018. View Article : Google Scholar : PubMed/NCBI

Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al: Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 537:417–421. 2016. View Article : Google Scholar : PubMed/NCBI

Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, et al: A pilot study of the PD-1 targeting agent AMP-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 18:e349–e360. 2019. View Article : Google Scholar : PubMed/NCBI

Nikitas J, Roach M, Robinson C, Bradley J, Huang J, Perkins S, Tsien C and Abraham C: Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Clin Transl Radiat Oncol. 21:32–35. 2019.PubMed/NCBI

Rodríguez Plá M, Dualde Beltrán D and Ferrer Albiach E: Immune checkpoints inhibitors and SRS/SBRT synergy in metastatic non-small-cell lung cancer and melanoma: A systematic review. Int J Mol Sci. 22:116212021. View Article : Google Scholar : PubMed/NCBI

Shields MD, Chen K, Dutcher G, Patel I and Pellini B: Making the rounds: Exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 23:90062022. View Article : Google Scholar : PubMed/NCBI

Spaas M, Sundahl N, Hulstaert E, Kruse V, Rottey S, De Maeseneer D, Surmont V, Meireson A, Brochez L, Reynders D, et al: Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): Study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer. 21:5142021. View Article : Google Scholar : PubMed/NCBI

Ni J, Yang L, Zhu H, Chu M, Zhang C, Zhao W, Yang M, Xu X, Zheng E, Jiang X, et al: A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: A case report. Ann Palliat Med. 10:4999–5009. 2021. View Article : Google Scholar : PubMed/NCBI